博济医药
(300404)
| 流通市值：41.40亿 | | | 总市值：55.93亿 |
| 流通股本：2.86亿 | | | 总股本：3.86亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 454,140,244.6 | 220,156,809.56 | 868,644,086.02 | 584,317,656.85 |
| 营业总成本 | 420,072,140.2 | 196,959,149.06 | 822,637,193.21 | 554,800,483.18 |
| 其他经营收益 | | | | |
| 营业利润 | 40,322,947.3 | 19,684,927.64 | 31,283,176.16 | 18,609,104.55 |
| 利润总额 | 40,264,447.44 | 19,680,239.72 | 30,056,670.56 | 18,330,632.81 |
| 净利润 | 37,748,290.32 | 16,070,215.53 | 32,909,794.36 | 23,867,516.19 |
| 每股收益 | | | | |
| 其他综合收益 | -1,391,854.46 | -242,885.29 | -1,199,416.73 | -395,881.93 |
| 综合收益总额 | 36,356,435.86 | 15,827,330.24 | 31,710,377.63 | 23,471,634.26 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,031,553,332.33 | 1,008,840,033.81 | 960,724,956.28 | 924,618,199.25 |
| 非流动资产: | | | | |
| 非流动资产合计 | 664,190,549.59 | 662,236,062.82 | 668,701,598.61 | 663,301,584.37 |
| 资产总计 | 1,695,743,881.92 | 1,671,076,096.63 | 1,629,426,554.89 | 1,587,919,783.62 |
| 流动负债: | | | | |
| 流动负债合计 | 538,066,195.06 | 524,281,728.66 | 525,328,069.83 | 486,863,233.71 |
| 非流动负债: | | | | |
| 非流动负债合计 | 43,013,266.15 | 44,928,754.95 | 44,555,217.44 | 46,944,774.6 |
| 负债合计 | 581,079,461.21 | 569,210,483.61 | 569,883,287.27 | 533,808,008.31 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,083,745,233.19 | 1,068,006,274.73 | 1,025,288,709.72 | 1,020,241,096.25 |
| 股东权益合计 | 1,114,664,420.71 | 1,101,865,613.02 | 1,059,543,267.62 | 1,054,111,775.31 |
| 负债和股东权益合计 | 1,695,743,881.92 | 1,671,076,096.63 | 1,629,426,554.89 | 1,587,919,783.62 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 462,103,380.93 | 196,489,320.6 | 930,272,019.98 | 616,381,565.15 |
| 经营活动现金流出小计 | 459,011,071.23 | 207,618,731.5 | 843,263,703.44 | 608,586,590.25 |
| 经营活动产生的现金流量净额 | 3,092,309.7 | -11,129,410.9 | 87,008,316.54 | 7,794,974.9 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 346,916,526.44 | 98,264,634 | 483,484,629.69 | 356,277,066.23 |
| 投资活动现金流出小计 | 410,671,683.6 | 273,578,088.43 | 529,887,165.36 | 507,723,089.39 |
| 投资活动产生的现金流量净额 | -63,755,157.16 | -175,313,454.43 | -46,402,535.67 | -151,446,023.16 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 34,187,750.76 | 26,945,761.41 | 71,311,857.84 | 68,948,873.07 |
| 筹资活动现金流出小计 | 13,949,650.13 | 2,530,543.58 | 54,383,269.23 | 50,355,688.99 |
| 筹资活动产生的现金流量净额 | 20,238,100.63 | 24,415,217.83 | 16,928,588.61 | 18,593,184.08 |
| 汇率变动对现金及现金等价物的影响 | -950,087.85 | -490,207.28 | -662,292.83 | -333,707.79 |
| 现金及现金等价物净增加额 | -41,374,834.68 | -162,517,854.78 | 56,872,076.65 | -125,391,571.97 |
| 期末现金及现金等价物余额 | 284,055,872.8 | 162,912,852.7 | 325,430,707.48 | 143,167,058.86 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -41,374,834.68 | - | 56,872,076.65 | - |